The Food and Drug Administration has issued another tranche of warning letters to telehealth companies selling compounded GLP-1 products, and the violations cited are almost word-for-word the marketing copy that has driven the direct-to-consumer weight-loss boom.
What Happened
The letters follow a template the agency has refined since September 2025. FDA reviewed seller websites and found claims that a compounded semaglutide or tirzepatide product contains "the same active ingredient" as Wegovy, Ozempic, Zepbound or Mounjaro — phrasing the agency reads as an implication of sameness, equivalence or approval.
FDA's legal position is narrow and consistent: compounded drugs are not FDA-approved. The agency does not review their safety, effectiveness or quality before they reach patients. A compounded drug does not become approved because its active ingredient matches one that is, and it is not a generic.
The letters identify two recurring patterns:
- Sameness claims that imply the compounded product is the same as, equivalent to, or interchangeable with a brand-name GLP-1.
- Obscured sourcing — advertising a drug under the telehealth firm's own name or trademark without qualification, implying the seller is the compounder rather than a marketer buying from an unknown facility.
FDA officials have said the agency is watching misleading claims across all media and acting quickly, while conceding that compounding can serve legitimate needs during shortages. The distinction it keeps drawing is between compounding and marketing that circumvents approval.
Who Is Affected
The immediate recipients are telehealth operators, who get 15 business days to respond with corrective action. Behind them sit the 503A and 503B facilities that supply the vials, whose names rarely appear on the websites FDA quotes.
Patients are the third group. A seller that markets its product as interchangeable with an approved drug has little incentive to explain where the API was sourced, whether fill volume matches the label, or which laboratory ran the assay.
Timeline
- September 2025 — FDA launches a crackdown on misleading direct-to-consumer pharmaceutical advertising, sending roughly 50 warning letters to telehealth providers in a single week.
- March 3, 2026 — a second formal tranche of 30 letters, with FDA stating that it had sent thousands of letters over six months, more than in the entire preceding decade.
- June 16, 2026 — 25 more letters posted, again centered on sameness phrasing and compounder identity.
- November 2026 — another round reported, extending a campaign that has not slowed.
By the agency's own count, its warning-letter database holds 113 telehealth-subject letters since September 2025; 110 of them mention a GLP-1 drug.
What This Means for Researchers
A warning letter is an administrative action, not a ban. FDA's own manual calls these letters informal and advisory, and they do not commit the agency to enforcement. What they do is set a documentation standard that buyers can apply immediately: a supplier that cannot name its compounder, its API source and its testing laboratory is a supplier whose marketing claims have already been judged misleading by the regulator.
How to Verify Your Peptides
Ask for a batch-specific certificate of analysis, the name of the third-party laboratory, and the analytical method used. Our guides walk through what each document should contain:
Safe Alternatives
If the goal is a documented, traceable product, start from compound reference pages on our peptides directory and compare suppliers listed in our vendor directory, where testing transparency is part of the profile.
Sources
Regulatory announcements (FDA warning letter database and press announcements); industry reports on compounding enforcement and telehealth marketing.